The inhibition in tumor growth was therefore probably due to the inhibition of the three established targets (VEGFR1, VEGFR3, and PDGFRβ), leading to the inactivation of alternative pathways to the ERK pathway and, subsequently, to a decrease in tumor growth. Here, FLT4 is linked to neoplasm.